Adagio Medical Holdings, Inc. (ADGM)
NASDAQ: ADGM · Real-Time Price · USD
0.9702
+0.0163 (1.71%)
At close: Jan 9, 2026, 4:00 PM EST
0.9103
-0.0599 (-6.17%)
After-hours: Jan 9, 2026, 6:11 PM EST
Adagio Medical Holdings Revenue
Adagio Medical Holdings had revenue of $137.00K in the twelve months ending September 30, 2025, down -74.77% year-over-year. In the year 2024, Adagio Medical Holdings had annual revenue of $602.00K with 100.67% growth.
Revenue (ttm)
$137.00K
Revenue Growth
-74.77%
P/S Ratio
106.98
Revenue / Employee
$1,713
Employees
80
Market Cap
20.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 602.00K | 302.00K | 100.67% |
| Dec 31, 2023 | 300.00K | 111.00K | 58.73% |
| Dec 31, 2022 | 189.00K | -81.00K | -30.00% |
| Dec 31, 2021 | 270.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionADGM News
- 18 days ago - Adagio Medical Appoints Two Seasoned Senior Executives to Accelerate Commercial Readiness - Business Wire
- 4 weeks ago - Adagio Medical Appoints Industry Veteran Sean Salmon to Board of Directors - Business Wire
- 2 months ago - Adagio Medical Reports Third Quarter 2025 Results - Business Wire
- 2 months ago - Adagio Medical to Present at the Piper Sandler 37th Annual Healthcare Conference - Business Wire
- 2 months ago - Adagio Medical Closes Financing of $19 Million Upfront; Positions Company to Advance Purpose-Built Technology for Treatment of Ventricular Tachycardia - Business Wire
- 3 months ago - Adagio Medical Announces Pricing of up to $50 Million Private Placement of Securities - Business Wire
- 3 months ago - Adagio Medical Unveils Preliminary Acute Results from FULCRUM-VT U.S. Pivotal Study in Late Breaking Session at VT Symposium - Business Wire
- 3 months ago - Adagio Medical, Inc. Announces Completion of Enrollment for FULCRUM-VT Pivotal Clinical Trial Evaluating Ultra-Low Temperature Cryoablation for Ventricular Tachycardia - Business Wire